-+ 0.00%
-+ 0.00%
-+ 0.00%
GSK Wins Japan's Orphan Drug Designation for Velzatinib in Gastrointestinal Stromal Tumor
Share
Listen to the news
02:49 AM EST, 11/19/2026 (MT Newswires) -- GSK (GSK.L) secured orphan drug designation for velzatinib as a treatment for gastrointestinal stromal tumor, or GIST, in Japan, according to a Thursday release. The designation from the Japanese Ministry of Health Labour and Welfare was based on the UK-listed drugmaker's ongoing phase 1/1b Strategist 1 study in people with advanced GIST, in which velzatinib demonstrated "promising" anti-tumor activity and tolerability profile. GSK is also evaluating velzatinib in late-stage studies as a first- and second-line treatment for advanced or metastatic GIST. Patient enrollment for the second-line treatment setting is ongoing, with data expected to be available in the second half.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending